InterMune (FRA:IUX) Forward Dividend Yield % : 0.00% (As of Sep. 24, 2024)

View and export this data going back to . Start your Free Trial

What is InterMune Forward Dividend Yield %?

As of today (2024-09-24), the Forward Annual Dividend Yield of InterMune is 0.00%.

As of today (2024-09-24), the Trailing Annual Dividend Yield of InterMune is 0.00%.

FRA:IUX's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.605
* Ranked among companies with meaningful Forward Dividend Yield % only.

InterMune's Dividends per Share for the three months ended in Jun. 2014 was €0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of InterMune's Forward Dividend Yield %

For the Biotechnology subindustry, InterMune's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InterMune's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InterMune's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where InterMune's Forward Dividend Yield % falls into.

InterMune Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

InterMune (FRA:IUX) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

InterMune Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of InterMune's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

InterMune Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InterMune Inc (FRA:IUX) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.intermune.com

InterMune, Inc was incorporated in California in 1998 and reincorporated in Delaware in 2000 in connection with its initial public offering. InterMune is a biotechnology company focused on the research, development and commercialization of therapies in pulmonology and orphan fibrotic diseases. The Company's business is mainly focused on the development and commercialization of therapies within the specialized areas of pulmonology and orphan fibrotic diseases. It has an advanced-stage product candidate in pulmonology, pirfenidone that was granted marketing authorization effective February 2011 in all 27 member countries of the European Union for the treatment of adults with mild to moderate idiopathic pulmonary fibrosis. Pirfenidone is an orally active, small molecule compound under development for the treatment of idiopathic pulmonary fibrosis. Pirfenidone, a treatment for IPF, a progressive and fatal lung disease, has completed the global Phase 3 CAPACITY clinical development program. Actimmune is currently approved in the United States for the treatment of chronic granulomatous disease and severe, malignant osteopetrosis. Actimmune is also approved for commercial use in both indications in numerous other countries. CGD is a life-threatening congenital disorder that causes patients, mainly children, to be vulnerable to severe, recurrent bacterial and fungal infections. This results in frequent and prolonged hospitalizations and commonly results in death. Severe, malignant osteopetrosis is a life-threatening, congenital disorder that mainly affects children. This disease results in increased susceptibility to infection and an overgrowth of bony structures that might lead to blindness and/or deafness. The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products.

InterMune Headlines

No Headlines